Valneva: all 54 studies

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• VLA1553-403 Pregnancy Surveillance StudyEnrolling by invitationNCT07414524
• Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilEnrolling by invitationNCT07347002
• A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 YearsCompletedNCT06106581Phase 2Results posted
• Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)Active, not recruitingNCT04838444Phase 3Results posted
• Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy AdultsCompletedNCT04786444Phase 3Results posted
• Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy SubjectsCompletedNCT04671017Phase 1/2Results posted
• Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in AdultsCompletedNCT04546724Phase 3Results posted
• Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701CompletedNCT03576183Phase 2Results posted
• Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II StudyCompletedNCT02316470Phase 2Results posted
• Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedNCT01296360Phase 3Results posted
• Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedNCT01246479Phase 3Results posted
• Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine PatchCompletedNCT01067781Phase 2Results posted
• Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedNCT01047839Phase 3Results posted
• Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedNCT01041573Phase 3Results posted
• A/H5N1/LT Dose Ranging StudyCompletedNCT00908687Phase 2Results posted
• Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedNCT00776230Phase 3Results posted
• Traveler's Diarrhea (TD) Automated ProcessCompletedNCT00751777Phase 2Results posted
• Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedNCT00605085Phase 3Results posted
• Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00604708Phase 3Results posted
• Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedNCT00596271Phase 3Results posted
• Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51CompletedNCT00596102Results posted
• Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00595790Phase 3Results posted
• Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00595465Phase 3Results posted
• Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595309Phase 3Results posted
• Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595270Phase 3Results posted
• Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00594958Phase 3Results posted
• LT Vaccine Patch Self-Administration StudyCompletedNCT00565461Phase 2Results posted
• Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07254702
• Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilActive, not recruitingNCT07163845
• A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy ChildrenWithdrawnNCT07133178Phase 3
• Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy AdultsCompletedNCT06334393Phase 1
• A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)WithdrawnNCT06028841Phase 3
• VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 InfectionCompletedNCT05364242Phase 2/3
• COVID-19 Paediatric VLA2001-321 StudyWithdrawnNCT05298644Phase 2/3
• Safety and Immunogenicity of VLA2001 Adults Aged ≥56 YearsCompletedNCT04956224Phase 3
• COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222CompletedNCT04864561Phase 3
• Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy AdultsCompletedNCT03425149Phase 1
• Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy VolunteersCompletedNCT03382964Phase 1
• Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43CompletedNCT01563263Phase 2/3
• Immune Response in IXIARO Batch JEV09L37 Recipients Before and After RevaccinationWithdrawnNCT01559831Phase 1
• Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 VaccineCompletedNCT01353534Phase 1/2
• Safety Surveillance After Immunization With IXIAROCompletedNCT01335412
• An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84CompletedNCT01296386Phase 1
• This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedNCT01158599Phase 4
• Traveler's Diarrhea (TD) Vaccine Asia Efficacy StudyCompletedNCT01040325Phase 2
• Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy StudyCompletedNCT00993681Phase 3
• Study Assessing Immunogenicity and Safety of IC43 In Intensive Care PatientsCompletedNCT00876252Phase 2
• Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47CompletedNCT00873431Phase 1
• Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy VolunteersCompletedNCT00778388Phase 1
• Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy StudyCompletedNCT00672035Phase 2
• Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide VaccineCompletedNCT00602784Phase 2
• Virological Response Study of the HCV Vaccine IC41CompletedNCT00601770Phase 2
• A/H5N1 Dose Ranging Study With Adjuvant PatchCompletedNCT00532792Phase 1
• ETEC Logistics Trial (TREK)CompletedNCT00516659Phase 2

← Valneva overview and focus areas